Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
64.00    2.00 (3.23%)
Bid:
63.00
Ask:
65.00
Spread: 2.00 (3.175%)
Market Cap: £15.59m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Trading Update

16 Nov 2023 07:00

RNS Number : 6171T
MyCelx Technologies Corporation
16 November 2023
 

The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

16 November 2023

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Trading Update

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company transforming the environmental impact of industry, announces a trading update today.

 

The Company is pleased to announce it has been notified a project valued at $5.4 million to MYCELX has been awarded for deployment of its REGEN media during oil production to meet the strict requirements for overboard discharge. The Company expects a formal purchase order in this regard in the coming days. REGEN was exclusively specified for this project because of its ability to reliably meet the strict water purity requirements of its client and regulations. Whilst the Company will not recognise revenue from the sale of the new equipment and media until 2024, this award will further solidify our position as a leader in clean production technology.

 

Following a robust performance for the first half of 2023, which included a number of project wins and new trials being signed, the Company continues to make progress in all of its target markets. However, unforeseeable events at two projects have impacted H2 2023 revenue. A variable volume dependent contract has not yet met anticipated volumes due to less plant activity. We expect the received volumes to ramp up as plant activity increases. Elsewhere, an unscheduled plant shut down led to the delay in the mobilisation of another project which we now anticipate will commence operations before year-end. As a result, revenue for 2023 is now expected to be in the range of $11.0 million - $11.8 million, against market expectations of $13.1 million. There are several other potential opportunities which could influence year-end revenue within the range, but final outturn is primarily dependent on the activity at these two projects. As a consequence, the Company also expects profitability for 2023 to be reduced versus previous market expectations.

 

Whilst we are disappointed in these unforeseen challenges, these longer duration projects underpin our outlook for next year. These projects together with our advance opportunity pipeline, increasing order book and legacy media sales enable us to increase our 2024 guidance to $17.5 million from market estimates of $14.9 million. The Company will provide further trading updates as we continue to build on the momentum in our core markets.

 

The Company is making progress in the PFAS market continuing with a landfill leachate trial in coordination with a global engineering and consulting company and a series of drinking water trials with a global water treatment company. Whilst we will continue to participate in these and other important trials in 2024, we expect to convert trials to project sales in 2024. Importantly, the U.S. EPA Administrator has recently stated the Agency is committed to finalising PFAS standards for drinking water by year-end 2023 which are expected to reduce the uncertainty that, the Company believes, has contributed to the delay of adoption of new technology and prevented enforcement of PFAS treatment for drinking water.

 

Connie Mixon, CEO, commented:

 

"Although we are revising our financial guidance for 2023, we believe that this is more than offset by the expected increase to revenue in 2024. Following a strong performance in H1 2023 we continue to make consistent progress in all of our core target markets and we are especially pleased by the new contract award for deploying our REGEN media. The Company is poised to capture more projects in this active market where awareness of our REGEN media's capability to support higher production levels and cleaner water is taking hold. We look forward to updating investors on material developments in all of our core markets when we can.

 

As a business, we continue to benefit from our proprietary technology that allows our clients to maximise their operational performance while minimising their environmental impact. These tailwinds leave us well positioned as we head into 2024, as we look to aggressively pursue projects where we have a differentiator, can leverage strategic partnerships and deliver value to our customers and stakeholders."

 

For further information, please contact: 

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nomad and Sole Broker)

Henry Fitzgerald-O'Connor

Gordon Hamilton

 

 

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

Tel: +44 20 7770 6424

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKPBDCBDDFDD
Date   Source Headline
3rd Jun 20267:00 amRNSAppointment of Non-Executive Director
12th May 20267:00 amRNSNew Gulf of Mexico Lease Award with Super Major
7th May 20267:00 amRNSFinal Results for the Year Ending 31 December 2025
16th Feb 202610:46 amRNSDirector Dealing
20th Jan 20267:00 amRNSTrading Update
22nd Dec 202511:27 amRNSHolding(s) in Company
7th Nov 20252:51 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNSTrading Update & $3.9m Project Award
1st Oct 20257:00 amRNSHolding(s) in Company
23rd Sep 20255:00 pmRNSResult of Annual Meeting
23rd Sep 20257:00 amRNSAppointment of New Chairman and Succession
17th Sep 20257:00 amRNSHalf Year Results Statement
11th Sep 20257:00 amRNSClosure of Restricted Stock Line
22nd Aug 20257:00 amRNSMailing of Notice of 2025 Annual Meeting
20th Aug 20257:00 amRNSOpening of $500,000 Line of Credit
17th Jul 20257:00 amRNSTrading Update
10th Jun 20257:00 amRNSMailing of 2024 Annual Report
21st May 20253:25 pmRNSDirector Dealing
19th May 202511:33 amRNSHolding(s) in Company
15th May 202511:21 amRNSHolding(s) in Company
12th May 20257:00 amRNSFinal Results for the Year Ending 31 December 2024
6th May 20257:00 amRNSPFAS Contract Award
1st May 20257:00 amRNS-REPA Announces Actions to Combat PFAS Contamination
10th Apr 20257:00 amRNSGrant of Share Options
7th Apr 20257:00 amRNSOperational and Trading Update
30th Jan 20257:00 amRNSChange of Adviser
6th Jan 20257:00 amRNSYear-end Update
29th Oct 20247:00 amRNSProject Award
24th Sep 20247:00 amRNSHalf Year Results Statement
23rd Sep 20247:00 amRNSTrading Update
6th Sep 202411:54 amRNSHolding(s) in Company
5th Sep 20245:17 pmRNSHolding(s) in Company
30th Aug 20247:00 amRNSBroker Option
23rd Aug 202411:05 amRNSDirector Dealings & Total Voting Rights
23rd Aug 20247:00 amRNSProposed Placing and Subscription
19th Jul 202410:36 amRNSPFAS Update
9th Jul 20242:23 pmRNSResult of AGM
9th Jul 20241:39 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNS2023 Annual Report & Notice of 2024 Annual Meeting
21st May 20247:00 amRNSDirector Dealing
16th May 20247:00 amRNSFinal Results for the Year Ending 31 December 2023
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.